HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,313,453 | +103704.9% | 86,740 | +38.7% | 0.02% | -32.0% |
| Q4 2022 | $3,192 | -99.9% | 62,557 | -3.0% | 0.02% | 0.0% |
| Q3 2022 | $3,005,000 | -5.0% | 64,525 | +2.1% | 0.02% | -3.8% |
| Q2 2022 | $3,164,000 | +12.8% | 63,192 | -2.5% | 0.03% | +30.0% |
| Q1 2022 | $2,806,000 | -3.9% | 64,802 | -25.6% | 0.02% | -4.8% |
| Q4 2021 | $2,921,000 | -15.7% | 87,123 | -2.3% | 0.02% | 0.0% |
| Q3 2021 | $3,464,000 | -10.1% | 89,133 | -11.1% | 0.02% | -8.7% |
| Q2 2021 | $3,855,000 | -25.2% | 100,222 | -1.9% | 0.02% | -25.8% |
| Q1 2021 | $5,157,000 | -0.6% | 102,204 | -2.5% | 0.03% | -6.1% |
| Q4 2020 | $5,187,000 | +357.8% | 104,798 | +187.7% | 0.03% | +312.5% |
| Q3 2020 | $1,133,000 | -0.7% | 36,423 | -11.2% | 0.01% | -11.1% |
| Q2 2020 | $1,141,000 | +20.0% | 41,034 | +1.0% | 0.01% | 0.0% |
| Q1 2020 | $951,000 | – | 40,615 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |